Background. Studies have shown thatperoxisome proliferator-activated receptor-γ (PPAR-γ) agonists could ameliorate renal fibrotic lesions in both diabetic nephropathy and nondiabetic chronic kidney diseases. Here, PPARG is linked to diabetic kidney disease.